X

Drug Profile

PF 06763809

Alternative Names: PF06763809

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Karo Pharma AB; Pfizer
Developer Pfizer
Class Antipsoriatics
Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Plaque psoriasis

Most Recent Events

13 Feb 2020 Pfizer terminates its research collaboration and license agreement with Karo Pharma
12 Nov 2019 Discontinued - Phase-I for Plaque psoriasis in Germany (Topical)
06 Nov 2019 Karo Bio and Pfizer terminates development of PF 06763809 for Autoimmune disorders

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com